Stress (linguistics)

CLINUVEL Trial Results Show Drug Reduces DNA Damage

Retrieved on: 
Sunday, January 15, 2023
EPP, Swelling, Afamelanotide, Skin cancer, Sunburn, Xeroderma pigmentosum, DNA, Stress (linguistics), Xeroderma, Skin, Risk, DNA repair, Patient, Hormone, Physician, Life expectancy, Clinical trial, Melanocortin, Pigment, Inflammation, XP, Light, Disorder, Pharmaceutical industry, Dietary supplement, Black Beach

MELBOURNE, Australia, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Results from a clinical trial in a genetic DNA repair disorder show that a new drug – afamelanotide – may be able to reduce the development of skin cancers.

Key Points: 
  • MELBOURNE, Australia, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Results from a clinical trial in a genetic DNA repair disorder show that a new drug – afamelanotide – may be able to reduce the development of skin cancers.
  • The trial results are the first showing the potential of afamelanotide, a melanocortin drug under development by CLINUVEL, to protect and treat patients with xeroderma pigmentosum (XP), a rare disorder which causes extreme rates of skin cancers and forces patients to live in the dark.
  • “Our first clinical trial results demonstrate that afamelanotide in adult XP patients can reduce key markers of light and ultraviolet DNA damage, suggesting we may be able to reduce the risk and frequency of skin cancers in these patients.”
    Xeroderma pigmentosum affects patients’ ability to repair DNA skin damage following exposure to light, particularly ultraviolet (UV) radiation.
  • Note to media: CLINUVEL has released further investor and technical releases on results from the CUV156 study.

Orlando Magazine Names Physio Flex Pro The Best Overall Joint Supplement

Retrieved on: 
Wednesday, November 9, 2022
Pleasure, GLOBE, LTD, Arthralgia, Swelling, Tendon, Research, Selenium, Therapy, Tissue, Stress (linguistics), Ligament, Cartilage, GMO, Movement, Joint, Inflammation, Glucosamine, Athlete, Pains, Pain, SRS, Motion, Industry, USA FDA, Dietary supplement, Cosmetics, Chondroitin

London, UK, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Orthopedic group approved and supported by distinguished athletes and leading physical therapists, Physio Flex Pro is the top rated over the counter joint supplement that offers total joint support.

Key Points: 
  • London, UK, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Orthopedic group approved and supported by distinguished athletes and leading physical therapists, Physio Flex Pro is the top rated over the counter joint supplement that offers total joint support.
  • Orlando Magazine, which is dedicated to delivering its readers with compelling local content that is both entertaining and informative, has now named Physio Flex Pro the best overall joint supplement of 2022/23.
  • It is no surprise that with support from Olympic athletes and industry respected physio therapists, as well as its unrivalled quality from using only high grade GMO-free active ingredients, that this leading joint supplement has received recognition as Orlando Magazine best joint supplement .
  • Physio Flex Pro is produced without soy, additives, bulk and fillers, instead prioritizing quality, and effective substances that will benefit your joints in unique ways.

Castle Creek Biosciences Announces Publication of Preclinical Study for Potential In Vivo Gene Therapy in Nature Communications

Retrieved on: 
Tuesday, August 30, 2022
Paragon, Connective tissue, Mayo Clinic, Liver failure, Cirrhosis, HCC, Research, Hepatocyte, Lists of diseases, Liver, Doctor of Philosophy, Tyrosine, Disease, Hope, Hepatocellular carcinoma, Skin, FAH, Stress (linguistics), Genome, Nature Communications, Liver disease, MD, Fibrosis, Patient, Biology, St. John's Hospital (Maplewood, Minnesota), Regenerative medicine, Mayo, Clinical trial, Tyrosinemia, Metabolism, Vaccine, Pharmaceutical industry, Medical imaging

EXTON, Pa., Aug. 30, 2022 /PRNewswire/ -- Castle Creek Biosciences announced publication of a preclinical study that found that its experimental in vivo gene therapy treatment resolved biochemical and hepatic histological markers of hereditary tyrosinemia type-1 (HT1) in a large animal model of the disease. The findings appear in the August 25 edition of Nature Communications.

Key Points: 
  • EXTON, Pa., Aug. 30, 2022 /PRNewswire/ --Castle Creek Biosciences announced publication of a preclinical study that found that its experimental in vivo gene therapy treatment resolved biochemical and hepatic histological markers of hereditary tyrosinemia type-1 (HT1) in a large animal model of the disease.
  • Castle Creek Biosciences in vivo gene therapy platform featured in Nature Communications.
  • The direct in vivo delivery of a single intraportal dose of the vector carrying the human FAH gene normalized liver function 78-98 days post-treatment, according to the published study.
  • Castle Creek Biosciences is a late-stage cell and gene therapy company developing treatments for skin, connective tissue and metabolic diseases.

New Research Uncovers Digital Security Opportunity for Banks and Credit Unions

Retrieved on: 
Tuesday, June 28, 2022
Professional Services, Security, Technology, Finance, Banking, Internet, Human Security Report Project, Fraud, Identity, Identity theft, TransUnion, Industry, Automation, PII, Organization, Financial services, Solution, AI, Stress (linguistics), Education, Internet, Online shopping

Al Pascual, senior vice president of enterprise risk solutions at Sontiq, said credit union members and bank customers are increasingly looking to financial institutions for help.

Key Points: 
  • Al Pascual, senior vice president of enterprise risk solutions at Sontiq, said credit union members and bank customers are increasingly looking to financial institutions for help.
  • Financial institutions can combat increased identity risks with personalized, self-service tools that are seamlessly embedded into the digital banking experience.
  • Among the many risks this opens for credit unions and banks are serious synthetic identity fraud issues.
  • Pascual said, There is a real opportunity in the current climate for financial institutions to become the trusted resource people need.

iHerb House Brands Launch New Products

Retrieved on: 
Thursday, May 26, 2022
Inflammation, Vitamins & Minerals, Vitamin, Disease, Organic acid, Time-invariant system, Happiness, Multimedia, Stress (linguistics), Health, Antioxidant, Herbal, Technology, VMS, Collection, Skin care, Online shopping, Dietary supplement, Mineral

PASADENA, Calif., May 26, 2022 /PRNewswire/ -- iHerb, a global leader in health and beauty e-commerce, is happy to announce a new lineup of supplements and self-care items that launched this month. For the past 26 years, iHerb has been dedicated to offering earth's best-curated selection of quality health and wellness products, at the best possible value and these new launches further that mission.

Key Points: 
  • For the past 26 years, iHerb has been dedicated to offering earth's best-curated selection of quality health and wellness products, at the best possible value and these new launches further that mission.
  • With value-driven prices, iHerb is committed to health and wellness that is accessible for all.
  • California Gold Nutrition, Immune & Respiratory Care (30/90 ct) $10-$53 - Help boost your immune response with California Gold Nutrition Immune and Respiratory Care.
  • "We're excited about the launch of these new products from iHerb Brands.

Hoth Therapeutics Announces New Pipeline Asset, HT-TBI for Stroke and Traumatic Brain Injury

Retrieved on: 
Tuesday, April 19, 2022
Cell death, Disability, U.S. Securities and Exchange Commission, Atopic dermatitis, Cerebral edema, Stroke, Lists of diseases, NASDAQ, Alzheimer's disease, Stress (linguistics), Annual report, Caregiver, Oxidative stress, Private Securities Litigation Reform Act, Military personnel, Brain, Organization, Anaphylaxis, Mast cell activation syndrome, Risk, Death, Patient, Inflammation, Health, Disease, TBI, Traumatic brain injury, Quality of life, Emergency, Therapy, Pharmaceutical industry, Hoth, Coronavirus

NEW YORK, April 19, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the company is adding a new asset to its pipeline portfolio, HT-TBI, which is based on scientific research performed by Hoth. HT-TBI is being developed as a novel, point-of-care therapy for the treatment of secondary brain injury (e.g., brain edema and inflammation) resulting from ischemic stroke and traumatic brain injury ("TBI"). HT-TBI will be developed as a ready-to-use drug-device combination product for use in non-healthcare settings by patients and caregivers at risk for stroke/TBI, emergency healthcare professionals, and military personnel.

Key Points: 
  • HT-TBI is being developed as a novel, point-of-care therapy for the treatment of secondary brain injury (e.g., brain edema and inflammation) resulting from ischemic stroke and traumatic brain injury ("TBI").
  • TBIs occur due to physical or mechanical trauma to the brain but are also associated with secondary brain injury (e.g., fluid/swelling, inflammation, oxidative damage, etc.).
  • The statistics of patients permanently impacted by stroke and TBI is astounding and Hoth is driven to reduce that burden."
  • Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs.

India Chiller (Scroll & Reciprocating, Screw, Centrifugal, Absorption) Markets, Competition, Forecast & Opportunities, FY2027 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 9, 2022
Other Manufacturing, Manufacturing, Scroll, Screw, Stress (linguistics), Dry cleaning, Absorption

India chiller market is expected to grow at a steady CAGR during the forecast period.

Key Points: 
  • India chiller market is expected to grow at a steady CAGR during the forecast period.
  • The India chiller market is driven by the flourishing food & beverage industry in the country.
  • To classify and forecast India chiller market based on product type, heat load, end use, company and regional distribution.
  • To identify and analyze the profile of leading players operating in India chiller market.

Agios Presents Mitapivat Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis in Non-transfusion-dependent α- and β-Thalassemia at 63rd ASH Annual Meeting and Exposition

Retrieved on: 
Monday, December 13, 2021
U.S. Securities and Exchange Commission, FDA, Investor, AES, Thalassemia, University of Toronto, Population, Host, Private Securities Litigation Reform Act, Jaundice, Sale, Splenectomy, Hemolysis, PRO, COVID-19, EMA, Stress (linguistics), NASDAQ, Fatigue, Macrocytic anemia, SEC, Pharmacokinetics, Hemolytic anemia, Life expectancy, Marketing, Safety, Goal, Patient, Disease, Exposition, Enzyme, Patent, Society, Transfusion-dependent anemia, Risk, University, GLOBE, ASH, Trial of the century, Iron overload, Erythropoiesis, Communication, University Health Network, Pharmaceutical industry, Risk management, Blood product

CAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today reported data for the first time from the ongoing long-term extension period of the Phase 2 open-label study of mitapivat, a first-in-class, investigational, oral, small molecule allosteric activator of wild-type and a variety of mutated pyruvate kinase (PK) enzymes, in adults with non-transfusion dependent α- or β-thalassemia. Data from the study were featured in an oral presentation at the American Society of Hematology (ASH) Annual Meeting and Exposition, hosted virtually and in person from Dec. 11-14, 2021, in Atlanta.

Key Points: 
  • Data from the study were featured in an oral presentation at the American Society of Hematology (ASH) Annual Meeting and Exposition, hosted virtually and in person from Dec. 11-14, 2021, in Atlanta.
  • Consistent with previously reported data , durable improvements in hemoglobin concentration and markers of hemolysis and ineffective erythropoiesis, were observed for up to 72 weeks of treatment in both - and -thalassemia patients.
  • Mitapivat was well tolerated, and the safety profile was consistent with previous studies.
  • The data presented today continue to demonstrate that chronic treatment with mitapivat is well tolerated and has the potential to meaningfully improve hallmarks of thalassemia, including hemolysis and ineffective erythropoiesis.

Solabia-Algatech Nutrition's Astaxanthin Multiblend Promotes Post-Exercise Muscle Pain

Retrieved on: 
Monday, November 22, 2021
Myopathy, CEO, Phospholipid, Protein, Environment, The Non-GMO Project, Exercise, Muscle, Pyridoxine, Vitamin, Smart contract, Myalgia, Health, Vitamin B6, DOMS, Microalgae, Biology, Glycerol, Athlete, Astaxanthin, Doctor of Philosophy, Cramp, Hard-shell taco, Pain, Glycogen, Oxidative stress, Magnesium, Risk, Stress (linguistics), Chemistry (relationship), Haematococcus, Tablet, MAX, Glucose, Fatigue, Dietary supplement, Management, Aquaculture

KIBBUTZ KETURA, Israel, Nov. 22, 2021 /PRNewswire/ -- Solabia-Algatech Nutrition unveils its new, multi-blend AstaPure MAX®, designed to reduce post-exercise muscle pain and fatigue. The new formula is centered on its flagship Astapure Arava® whole-algae complex, which delivers natural astaxanthin along with essential nutrients. It is combined with easily absorbed magnesium glycerophosphate and vitamin B6 (pyridoxine). The formula's positive effect on physical resilience was demonstrated in a recent 8-week survey study conducted by the company.

Key Points: 
  • KIBBUTZ KETURA, Israel, Nov. 22, 2021 /PRNewswire/ -- Solabia-Algatech Nutrition unveils its new, multi-blend AstaPure MAX , designed to reduce post-exercise muscle pain and fatigue.
  • The new formula is centered on its flagship Astapure Arava whole-algae complex, whichdelivers natural astaxanthin along with essential nutrients.
  • The pain that ensues is commonly referred to as "Delayed-Onset Muscle Soreness" (DOMS)and can signal damage to muscle tissues.
  • "As a world leading manufacturerof astaxanthin, our goal is to keep bringing astaxanthin-centered innovation to the market.

Healthy Extracts Launches High-Potency Organic Citrus Bergamot Formulations with Clinically Proven Heart Benefits, Available Exclusively on Amazon

Retrieved on: 
Wednesday, October 20, 2021
Triglyceride, Immune system, Risk, Metabolism, Woman, CDC, Krka (company), UBN, Private Securities Litigation Reform Act, Memory, Person, Blood pressure, News, Rosuvastatin, OTCQB, Flavonoid, Achievement, Canadian International Council, Cardiology, BPF, Ageing, Annual report, Ultimate Brain, Disease, The Non-GMO Project, Superfood, IP, Sale, FDA, Citrus, Stress (linguistics), GLOBE, Health, Polyphenol, Degenerative disease, Forward-looking statement, International Journal of Cardiology, SEC, Heart, Tablet, Cognition, Company, Perfume, Pharmaceutical industry, Dietary supplement, Fine chemical

LAS VEGAS, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Healthy Extracts Inc. (OTCQB: HYEX), a leading innovator of clinically proven plant-based products for heart and brain health, has launched two new high-potency natural formulations, Organic Citrus Bergamot for Women and Organic Citrus Bergamot , available today only on Amazon.

Key Points: 
  • LAS VEGAS, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Healthy Extracts Inc. (OTCQB: HYEX), a leading innovator of clinically proven plant-based products for heart and brain health, has launched two new high-potency natural formulations, Organic Citrus Bergamot for Women and Organic Citrus Bergamot , available today only on Amazon.
  • Offered exclusively in North America by Healthy Extracts, Citrus Bergamot SuperFruit has the highest quality and concentration of polyphenols and flavonoids (BPF).
  • Designed to be naturally effective for womens health, Organic Citrus Bergamot for Women contains highly concentrated citrus bergamot tablets with a daily dosage of 1,500 milligrams.
  • Organic Citrus Bergamot is suitable for anyone looking to improve their health and wellness by providing a daily dosage of 1,500 milligrams of Citrus Bergamot SuperFruit.